DSIP 5 mg Vial Dosage Protocol

DSIP (5 mg Vial) Dosage Protocol

At a Glance

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid neuropeptide studied for its ability to promote deep delta-wave sleep and modulate the HPA axis. Published human research used intravenous administration; community researchers typically use subcutaneous injection at lower doses extrapolated from animal data.[1]

  • Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2,500 mcg/mL) concentration.
  • Standard dose: 200 mcg before sleep subcutaneous injection, 30–60 minutes prior to sleep.
  • Easy measuring: At 2.5 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 25 mcg. A 200 mcg dose = 8 units / 0.08 mL.
  • Doses per vial: 25 doses at 200 mcg standard; use within 4 weeks of reconstitution.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

How to Mix & Dose

Everything you need to reconstitute and dose DSIP from a 5 mg vial

Dosing Schedule

Phase Dose Units (U-100) Volume Timing
Starting (Nights 1–5) 100 mcg 4 units 0.04 mL 30–60 min before sleep
Standard 200 mcg 8 units 0.08 mL 30–60 min before sleep
High 300 mcg 12 units 0.12 mL 30–60 min before sleep

Reconstitute each 5 mg vial with 2.0 mL bacteriostatic water for a concentration of 2.5 mg/mL (1 unit on a U-100 syringe = 25 mcg). Administer subcutaneously 30–60 minutes before intended sleep time. Published human research documented cumulative benefit across 3–4 administrations; many researchers use DSIP 3–4 nights per week rather than nightly. DSIP is not intended for daytime use.[1]

How to Reconstitute

  1. Allow frozen vial to reach room temperature (10–15 minutes).
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; do not inject directly onto the lyophilised cake.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

What You’ll Need

Plan based on a 30-day course at 200 mcg, 4 nights per week (approx. 17 injections, 3,400 mcg total).

  • DSIP Vials (5 mg each): 3,400 mcg ÷ 5,000 mcg per vial → 1 vial (25 doses per vial at 200 mcg).
  • Insulin Syringes (U-100, 1 mL): 1 per injection → 17 syringes for the course.
  • Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle.
  • Alcohol Swabs: 2 per injection → 34 swabs for the course.

Overview

  • Goal: Promote deep delta-wave sleep via neuropeptide modulation of sleep architecture and HPA axis.[1]
  • Schedule: Subcutaneous injection 30–60 minutes before sleep; 3–4 nights per week recommended.
  • Dose: 100–300 mcg per injection (4–12 units / 0.04–0.12 mL); standard 200 mcg.
  • Reconstitution: 2.0 mL BAC water per 5 mg vial → 2.5 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

Dosing Details

  • Starting: 100 mcg (4 units / 0.04 mL) subcutaneous, 30–60 min before sleep for the first 5 nights.[2]
  • Standard: 200 mcg (8 units / 0.08 mL) subcutaneous, 30–60 min before sleep.
  • High: 300 mcg (12 units / 0.12 mL) subcutaneous, 30–60 min before sleep.
  • Frequency: 3–4 nights per week; not required nightly.
  • Injection site: Abdomen, thigh, or upper arm. Rotate sites between injections.
  • Note: An initial mild arousal effect may occur in the first hour; sleep-promoting effects typically emerge in the second hour.[2]

Storage

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy, discoloured, or particulate.

Good to Know

  • Published human research used intravenous administration at 25 nmol/kg (≈1.5 mg IV for 70 kg). Community subcutaneous dosing at 100–300 mcg is extrapolated from animal research — no human pharmacokinetic data for SC DSIP exists.
  • DSIP shows a U-shaped dose-response curve in animal models — both sub-optimal and supra-optimal doses may produce diminished or reversed effects. Start at the lower end and assess response over several nights before increasing.[3]
  • Cumulative benefit was observed across multiple administrations in human IV studies; results on a single night may be modest.
  • Do not use concurrently with opioid medications — DSIP has demonstrated opioid receptor activity and additive CNS/respiratory depression is theoretically possible.
  • Athletes subject to anti-doping rules should seek written confirmation from their Anti-Doping Organization before use; WADA Section S2 catch-all clauses may apply.

How DSIP Works

DSIP is a nine-amino-acid neuropeptide (WAGGDASGE; MW 849 Da) first isolated from the cerebral venous blood of sleeping rabbits by Schoenenberger & Monnier at the University of Basel in 1977.[1] The most distinctive feature of DSIP — and its primary scientific puzzle — is that its receptor has never been identified despite nearly five decades of research.

What is established: DSIP crosses the blood-brain barrier via both passive diffusion and a saturable transport system. It modulates the hypothalamic-pituitary-adrenal (HPA) axis, correlating with cortisol levels. It interacts with the pineal gland through N-acetyltransferase modulation, influencing melatonin synthesis. Its antinociceptive effects in animals are blocked by the opioid antagonist naloxone, suggesting functional interaction with opioid receptors.[4] The net result of these interactions — in the correct dose and timing window — is an enhancement of delta-wave (slow-wave) EEG activity and deeper sleep architecture.

Evidence Summary & What to Watch For

  • Sleep (human IV data): Weak but statistically significant improvements in sleep efficiency and onset latency in the only double-blind study (Bes et al. 1992, N=16); no subjective improvement was found.[2] Earlier open studies were more positive but less controlled.
  • Withdrawal (uncontrolled human data): 87–97% of 107 inpatients showed marked improvement in alcohol or opiate withdrawal symptoms (Dick et al. 1984); no placebo group was included.[5]
  • Pain (animal data): Supraspinal opioid-mediated analgesia confirmed in mice; no human analgesic trials exist.[4]
  • Neuroprotection (animal data): Intranasal DSIP accelerated motor recovery post-stroke in rats; Deltaran combination achieved 100% ischemia survival vs. 62% in controls.
  • First-hour arousal: An initial mildly arousing effect in the first hour post-injection is documented in human studies; do not expect immediate sedation.
  • No daytime sedation reported in any published human study.

Tips for Best Results

  • Administer 30–60 minutes before the intended sleep time to align with the delayed onset of sleep-promoting effects.
  • Minimize blue-light exposure and screen use in the 30–60 minutes post-injection to support the transition to sleep.
  • Maintain a consistent sleep schedule — DSIP modulates natural sleep architecture and works best when circadian rhythms are regular.
  • Start at 100 mcg and observe over 5 nights before increasing to 200 mcg; the U-shaped dose-response means more is not always better.
  • Adequate dietary magnesium and consistent wind-down routines complement sleep peptide research protocols.

Injection Tips

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold).[CDC]
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. DSIP is not approved for human therapeutic use. For research use only. All published human efficacy data used intravenous administration; subcutaneous dosing in humans is not validated in peer-reviewed literature.

References


  • Schoenenberger GA & Monnier M — PNAS (1977)
    Original isolation and characterization of DSIP; sequence WAGGDASGE confirmed; delta-wave sleep promotion demonstrated in rabbits
    View Source

  • Bes F et al. — Neuropsychobiology (1992)
    Best-controlled human trial; double-blind, 16 chronic insomniacs, 3 nights IV DSIP 25 nmol/kg; weak objective sleep improvements; initial arousal then sleep onset; no adverse events
    View Source

  • Graf MV & Kastin AJ — Neuroscience & Biobehavioral Reviews (1984)
    Comprehensive DSIP review; documents U-shaped dose-response curve and timing-dependency of effects
    View Source

  • Nakamura H et al. — European Journal of Pharmacology (1988)
    Opioid-mediated supraspinal analgesia by DSIP; naloxone-blocked; BBB penetration confirmed for CNS activity
    View Source

  • Dick P et al. — European Neurology (1984)
    107 inpatients; 87–97% marked improvement in alcohol/opiate withdrawal with IV DSIP; uncontrolled study
    View Source

  • Bachem Peptide Technical Guide
    Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    Subcutaneous injection technique, angle, and site rotation guidance
    View Source

Looking for research-grade DSIP 5 mg? Our sponsor White Market Peptides carries DSIP 5 mg with third-party purity testing. Use code PEPDOSE for 10% off + free 2-day shipping over $200.